Apellis Pharmaceuticals Inc ROIC
What is the ROIC of Apellis Pharmaceuticals Inc?
The ROIC of Apellis Pharmaceuticals Inc is -64.16%
What is the definition of ROIC?
Return on invested capital (ROIC) is a financial ratio that measures how efficient a company is at allocating the capital under its control to profitable investments.
= NOPAT / Invested capital = EBIT * (1 - tax rate) / (2-year average liabilities + 2-year average shareholder equity)
Return on invested capital (ROIC) ratio gives investors a sense of how well a company is using money under its control to generate profitable returns.
ROIC can be used as a benchmark to calculate the valuation of companies across industries. A higher ROIC means the company is doing a better job of investing the money from shareholders and bondholders to run the business. A company is creating value if its ROIC exceeds 2%. If its ROIC is under 2%, the company is likely destroying value and has no excess capital to invest in future growth.
You can calculate ROIC with the following formula:
NOPAT = Net operating profit after tax
Invested Capital = Average total liabilities + Average shareholders' equity
The averages of liabilities and shareholders' equity are calculated as geometrical averages of the last two annual values from the company's balance sheet.
ROIC of companies in the Health Care sector on NASDAQ compared to Apellis Pharmaceuticals Inc
What does Apellis Pharmaceuticals Inc do?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Companies with roic similar to Apellis Pharmaceuticals Inc
- Gritstone Bio Inc has ROIC of -64.25%
- POET Technologies has ROIC of -64.23%
- Interconnect Ventures has ROIC of -64.21%
- Marathon Patent has ROIC of -64.18%
- Skeena Resources has ROIC of -64.18%
- Transphorm has ROIC of -64.17%
- Apellis Pharmaceuticals Inc has ROIC of -64.16%
- Professional Diversity Network has ROIC of -64.13%
- Atomo Diagnostics has ROIC of -64.10%
- GeneNews has ROIC of -64.08%
- Dragon Victory International Ltd has ROIC of -64.05%
- OzAurum Resources has ROIC of -64.03%
- STARAMBA SE has ROIC of -64.01%